The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C.
 
Martin J. Edelman
Stock and Other Ownership Interests - Biomarker Strategies
Consulting or Advisory Role - ARIAD; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Endocyte (Inst); Genentech/Roche (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - ARIAD; Hospira; Lilly
Other Relationship - AstraZeneca/MedImmune; Boehringer Ingelheim; Lilly; Synta
 
Mary Weber Redman
Consulting or Advisory Role - Bristol-Myers Squibb
 
Kathy S. Albain
No Relationships to Disclose
 
Eric C. McGary
No Relationships to Disclose
 
Norman Rafique
No Relationships to Disclose
 
Daniel P. Petro
No Relationships to Disclose
 
Saiama Naheed Waqar
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Lilly (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Spectrum Pharmaceuticals (Inst); Stem CentRx (Inst); Synermore biologics (Inst); Vertex (Inst); Xcovery (Inst)
 
Jieling Miao
No Relationships to Disclose
 
Katie Griffin
No Relationships to Disclose
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - ARIAD; AstraZeneca; Biothera; Clovis Oncology; Genentech; Genentech; Gensignia Life Sciences; Janssen; Lilly; Merck
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Karen Kelly
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - ARIAD; ARIAD; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; G1 Therapeutics; Genentech/Roche; Lilly; Lilly; Synta
Research Funding - Abbvie (Inst); Celgene (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Millennium (Inst); Novartis (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Roche
 
David R. Gandara
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Celgene; Clovis Oncology; Genentech; Guardant Health; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; Response Genetics; Sanofi; Synta
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech (Inst); Johnson & Johnson (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Roy S. Herbst
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Lilly; Merck; Pfizer
Research Funding - Genentech; Merck